Drug Type Radiolabeled antibody, Therapeutic radiopharmaceuticals |
Synonyms 225Ac-HER3 ARC, Ac-225-HER3-ARC, Actinium-225-conjugated anti-HER3 antibody (Actinium Pharmaceuticals) |
Target |
Mechanism HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | US | 04 Apr 2023 | |
Kidney Neoplasms | Preclinical | US | 04 Apr 2023 | |
Ovarian Cancer | Preclinical | US | 04 Apr 2023 | |
Prostatic Cancer | Preclinical | US | 04 Apr 2023 | |
Neoplasms | Preclinical | - | 11 Apr 2022 |